Chapter

Systemic therapy for recurrent NSCLC, efficacy, and toxicity

Paul Wheatley-Price and Frances A. Shepherd

in Systemic Treatment of Non-Small Cell Lung Cancer

Published on behalf of Oxford University Press

ISBN: 9780199580484
Published online March 2012 | e-ISBN: 9780199607532 | DOI: http://dx.doi.org/10.1093/med/9780199580484.003.0006

Series: Oxford Oncology Library

Systemic therapy for recurrent NSCLC, efficacy, and toxicity

Show Summary Details

Preview

• Patients with advanced non-small-cell lung cancer are destined to progress at some point following first-line therapy • There are now multiple options for clinicians in the treatment of recurrent disease, using cytotoxic or biological therapies • Docetaxel, pemetrexed, erlotinib and gefitinib all have phase III trial evidence supporting their use, and multiple other agents or combinations are being studied • Identifiable patient and tumour characteristics will increasingly help to guide the selection of therapy in these patients.

Chapter.  4315 words. 

Subjects: Medical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.